FIRST-LINE PERTUZUMAB-BASED TREATMENT FOR HER2-POSITIVE METASTATIC BREAST CANCER IN FRANCE: A FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS) ANALYSIS
Author(s)
Thibaut de la Motte Rouge, MD, PhD1, Nadine DOHOLLOU, Dr2, Matthieu Carton, Dr3, Laurence ESCALUP, Dr4, Lydie LEMONNIER, -5, Pauline Macouillard, -5, Axelle MENU, Dr5, Claire JOUFFROY-ZELLER, -5, Anne-Laure MARTIN, -5, Solene JAILLARD, -6, Manoel Moreau, -7, Danko Stamenic, PhD8, Majda Le Foll-Elfounini, -8, Véronique DIERAS, Dr9.
1Centre Eugène-Marquis, Rennes, France, 2Oncology department, Polyclinique Bordeaux Nord, Bordeaux, France, 3Department of Biostatistics, Institut Curie, Saint-Cloud, Saint-Cloud, France, 4Pharmacy Department, Institut Curie, Paris, France, 5Health Data and Partnership Department, Unicancer, Paris, France, 6Medical Affairs Unit, Roche SAS, Boulogne-Billancourt, France, 7Medical Evidence & Data Science Unit, Roche SAS, Boulogne Billancourt, France, 8Medical Evidence & Data Science Unit, Roche SAS, Boulogne-Billancourt, France, 9Oncology department, Centre Eugène Marquis, Rennes, France.
1Centre Eugène-Marquis, Rennes, France, 2Oncology department, Polyclinique Bordeaux Nord, Bordeaux, France, 3Department of Biostatistics, Institut Curie, Saint-Cloud, Saint-Cloud, France, 4Pharmacy Department, Institut Curie, Paris, France, 5Health Data and Partnership Department, Unicancer, Paris, France, 6Medical Affairs Unit, Roche SAS, Boulogne-Billancourt, France, 7Medical Evidence & Data Science Unit, Roche SAS, Boulogne Billancourt, France, 8Medical Evidence & Data Science Unit, Roche SAS, Boulogne-Billancourt, France, 9Oncology department, Centre Eugène Marquis, Rennes, France.
OBJECTIVES: Dual HER2 blockade with pertuzumab and trastuzumab added to a taxane is standard first-line (1L) treatment of HER2+ metastatic breast cancer (mBC). The LongHER study investigated the real-world use of pertuzumab+trastuzumab 1L therapy for HER2+ mBC in France.
METHODS: This retrospective cohort study obtained French National Claims Database data for women ≥18 years with HER2+ mBC or locally recurrent, unresectable BC and no other prior cancer starting 1L pertuzumab+trastuzumab between 1-Jan-2014 and 31-Dec-2023. To distinguish metastatic from adjuvant settings, patients (pts) either had no record of BC surgery between 1-Jan-2008 and 31-Dec-2024 (de novo mBC) or had BC surgery between these dates and started pertuzumab+trastuzumab either ≥4 mo post-surgery, or <4 mo post-surgery and for >18 cycles (recurrent mBC). Endpoints were time-to-last-administration (TTLA), defined as time from first pertuzumab+trastuzumab dose until discontinuation or death; and overall survival (OS), treatment patterns, and patient characteristics. Median TTLA and OS were estimated by the Kaplan-Meier method.
RESULTS: 13,352 pts were included, with a median (Q1-Q3) age at 1L mBC treatment initiation of 60.0 years (50.0-70.0), of whom 47.9% (n=6391) had de novo mBC and 53.9% (n=7193) were HR+. Median (95% CI) follow-up time, TTLA and OS were 61.5 mo (60.4-63.0), 12.4 mo (12.0-12.6) and 55.5 mo (53.8-57.3), respectively. Of 10,281 pts (77.0%) with ≥36 mo follow-up, 21.9% remained on pertuzumab+trastuzumab-based treatment at 36 mo. In a sensitivity analysis (treatment discontinuation defined as the last dose of either pertuzumab or trastuzumab, whichever was stopped last, or death), 25.4% remained on anti-HER2 maintenance monotherapy at 36 mo, and of these, 61.2% were HR+. Treatment pattern data will be presented.
CONCLUSIONS: Dual anti-HER2 blockade for pts with mBC achieved real-world TTLA and OS similar to clinical trial results, and a significant proportion of pts were long responders (TTLA >36 mo).
METHODS: This retrospective cohort study obtained French National Claims Database data for women ≥18 years with HER2+ mBC or locally recurrent, unresectable BC and no other prior cancer starting 1L pertuzumab+trastuzumab between 1-Jan-2014 and 31-Dec-2023. To distinguish metastatic from adjuvant settings, patients (pts) either had no record of BC surgery between 1-Jan-2008 and 31-Dec-2024 (de novo mBC) or had BC surgery between these dates and started pertuzumab+trastuzumab either ≥4 mo post-surgery, or <4 mo post-surgery and for >18 cycles (recurrent mBC). Endpoints were time-to-last-administration (TTLA), defined as time from first pertuzumab+trastuzumab dose until discontinuation or death; and overall survival (OS), treatment patterns, and patient characteristics. Median TTLA and OS were estimated by the Kaplan-Meier method.
RESULTS: 13,352 pts were included, with a median (Q1-Q3) age at 1L mBC treatment initiation of 60.0 years (50.0-70.0), of whom 47.9% (n=6391) had de novo mBC and 53.9% (n=7193) were HR+. Median (95% CI) follow-up time, TTLA and OS were 61.5 mo (60.4-63.0), 12.4 mo (12.0-12.6) and 55.5 mo (53.8-57.3), respectively. Of 10,281 pts (77.0%) with ≥36 mo follow-up, 21.9% remained on pertuzumab+trastuzumab-based treatment at 36 mo. In a sensitivity analysis (treatment discontinuation defined as the last dose of either pertuzumab or trastuzumab, whichever was stopped last, or death), 25.4% remained on anti-HER2 maintenance monotherapy at 36 mo, and of these, 61.2% were HR+. Treatment pattern data will be presented.
CONCLUSIONS: Dual anti-HER2 blockade for pts with mBC achieved real-world TTLA and OS similar to clinical trial results, and a significant proportion of pts were long responders (TTLA >36 mo).
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH27
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology